Who are Recombinant Streptokinase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, Tranexamic Acid plus standard of care, Silymarin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-streptokinase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant Streptokinase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Streptokinase (Recombinant Streptokinase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular.

marketed Fibrinolytic agent / Thrombolytic Plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Streptokinase (Recombinant Streptokinase) — Beijing Chao Yang Hospital. Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant Streptokinase TARGET	Recombinant Streptokinase	Beijing Chao Yang Hospital	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Silymarin	Silymarin	F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica	marketed	silymarin	Urokinase-type plasminogen activator, Carbonic anhydrase 1, Carbonic anhydrase 12

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

All India Institute of Medical Sciences · 1 drug in this class
Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Beijing Chao Yang Hospital · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Life Recovery Systems · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Thrombolex, Inc. · 1 drug in this class
Tianjin Huanhu Hospital · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Streptokinase — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-streptokinase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab